Longeveron Inc. (LGVN)
$1.73-19.53%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $34M
- Beta
- -0.26
- P/E (TTM)
- -0.17
- Short % float
- 0.66%
- Days to cover
- 1.0
- SI change
- -50.0%
- 1W
- -29.10%
- 1M
- -74.78%
- vs SPY 1W
- -28.96%
- vs SPY 1M
- -77.29%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 13
- GROWTH
- 40
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-133.9%
REV YoY-
ROE-223.2%
EPS YoY-
ROA-151.6%
GROSS70
OP-1993
NET-1978
[VALUATION]
P/E TTM-0.17
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.52
P/FCF-
EV/EBITDA0.19
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.59
ALTMAN Z-
CURR RATIO2.63
ND/EBITDA-
BETA-0.26
Company news
FAQ
- What is LOPJLB’s current signal on LGVN?
- LOPJLB’s latest quantitative signal on Longeveron Inc. (LGVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LGVN in?
- Longeveron Inc. (LGVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Longeveron Inc. (LGVN) do?
- Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling c…